2016 Hematological Malignancies

RIC-Allo Trial in Relapsed or Refractory HL (Non-relapse Mortality)

Age >45 yrs, RR 2.4 (1.1 – 5.0), P = .05 Performance status ≥2, RR 3.9 (1.8 – 7.3), P = .05 Refractory disease, RR 2.6 (1.5 – 4.5), P = .01

0 0.2 0.4 0.6 0.8 1

8% at 100 days

15% at 1 yr

17% at 2 yrs

CI NRM

19% at 3 yrs

0

12

24

36

48

60

Time after RIC-allo, months

RIC-allo - reduced-intensity conditioning allogenic stem cell transplantation; HL – Hodgkin lymphoma; NRM – non-relapse mortality